Lv3
278 积分 2025-10-20 加入
Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective
1个月前
已完结
Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies
1个月前
已完结
Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China
1个月前
已完结
Survodutide Once Weekly for the Treatment of Adults with Obesity
2个月前
已完结
Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study
2个月前
已完结
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
2个月前
已完结
CONTINUED TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO SUSTAINED IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 4 TRIAL
2个月前
已完结
Survodutide Once Weekly for the Treatment of Adults with Obesity
3个月前
已完结
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
4个月前
已完结
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
4个月前
已完结
皖公网安备34019202002308
